Table 3.
Antiepileptic drugs and associated adverse effects among epileptic patients on AEDs at MTUTH from March 10 to April 10, 2018.
| Antiepileptic drug | Adverse effects | Frequency (%) |
|---|---|---|
| Types of AEDs used | Phenobarbitone alone | 90 (62.9) |
| Phenytoin alone | 23 (16.1) | |
| Phenobarbitone plus phenytoin | 17 (11.9) | |
| Phenobarbitone plus carbamazepine | 9 (6.3) | |
| Carbamazepine plus phenytoin | 4 (2.8) | |
| AEDs prescribed as initial therapy | Phenobarbitone | 117 (81.8) |
| Phenytoin | 22 (15.4) | |
| Carbamazepine | 4 (2.8) | |
| AEDs prescribed as add-on therapy | Phenytoin | 21 (14.7) |
| Carbamazepine | 12 (8.4) | |
| Polytherapy with AEDs | Yes | 30 (21.0) |
| No | 113 (79.0) | |
| Polytherapy irrespective of AEDs | Yes | 70 (48.9) |
| No | 73 (51.1) | |
| Antiepileptic-related adverse effects | Yes | 104 (72.7) |
| No | 39 (27.3) | |
| Types of antiepileptic associated adverse effects | Sedation | 78 (54.5%) |
| Confusion | 10 (7.0) | |
| Weakness | 9 (6.3) | |
| Gingival hyperplasia | 9 (6.3) | |
| Rash | 7 (4.9) | |
| Blurred vision | 6 (4.2) | |
| GI irritation | 4 (2.8) |